|
Novartis International AG |
|
|
Basel, CH-4002 Switzerland
phone:+41 61 324 11 11
fax:+1 +41 61 324 80 01
|
|
| Symbol |
NVS |
| Exchange |
NYSE |
| Founded |
1996 |
| Employees |
72877 |
|
|
| www.novartis.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide. |
|
| Management |
| Daniel Vasella, M.D., Chairman and CEO; Ulrich Lehner, Ph.D., Vice Chairman and Lead Director; Hans-Joerg Rudloff, Vice Chairman; William Brody, M.D; Ph.D.Srikant Datar, Ph.D. |
| |
|
|
|
|
|
|
|
| Keywords |
| diovan, hypertension, eucreas, galvus, lescol |
|
|
|
| Description |
|
Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz, two companies with a rich and diverse corporate history. Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide. Product includes vaccines and diagnostics, and other market innovative medicines with improved efficacy and fewer side-effects. Their Over-theCounter division (OTC) is a world leader in research, development, production, and marketing of self-medication products that do not require prescriptions and are designed for the in-home treatment and prevention of medical conditions and ailments. The main OTC product categories are analgesics, cough, cold, allergy, gastrointestinal, skin care and smoking-cessation treatments as well as mineral supplements. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
